SUMMARY
The mechanism that leads to a decrease in b 1 -adrenergic receptor (b 1 AR) expression in the failing heart remains uncertain. This study shows that cardiomyocyte b 1 AR expression and isoproterenol responsiveness decrease in response to oxidative stress. Studies of mechanisms show that the redox-dependent decrease in b 1 AR expression is uniquely prevented by carvedilol and not other bAR ligands. Carvedilol also promotes the accumulation of N-terminally truncated b 1 activation leads to a spectrum of changes (including cardiomyocyte hypertrophy/apoptosis, interstitial fibrosis, and contractile dysfunction) that contribute to the pathogenesis of heart failure (HF) (2) . bAR inhibitors that prevent maladaptive cAMP-driven bAR responses have become mainstays of HF therapy.
Although bAR activation provides hemodynamic support and compensates for the contractile dysfunction that develops in HF, chronic HF leads to a loss of cardiac reserve due to desensitization and/or down-regulation of bARs (2) . Decreased b 1 AR density is a hallmark of HF, but the mechanism underlying this adaptive mechanism remains uncertain because the classic paradigms for bAR regulation are based largely on studies of the b 2 AR subtype. Current models hold that agonists stabilize bARs in an active In the course of these studies, we also identified a heretofore unrecognized property of carvedilol, a bAR inhibitor that reportedly offers survival advantages over other bAR inhibitors in the treatment of HF (8) .
Earlier studies have argued that this finding might be attributable to carvedilol's ancillary properties as an antioxidant (9) or its unique pharmacologic profile;
carvedilol acts as an inverse agonist for the bAR-G scAMP pathway (i.e., it prevents catecholaminergicinduced cardiotoxicity) and a biased agonist for b-arrestin-mediated signaling to ERK and potentially other cardioprotective pathways (10, 11) . Our studies
show that carvedilol prevents b 1 AR redox inactivation and that it also triggers a novel b 1 AR-dependent cardioprotective mechanism. We recently found that b 1 ARs are detected as both full-length (FL) and Park and Steinberg Although there is precedent for a switch in the b 1 AR's G protein-coupling specificity from G s to G i (12) . Rather, Figure 5B shows that the increase in basal AKT phosphorylation in D2-52-b 1 AR overexpressing cardiomyocytes is completely abrogated by PTX, implicating a PTX-sensitive G i protein in this pathway. Collectively, Park and Steinberg Studies reported herein provide novel evidence that oxidative stress, a stimulus that contributes to the 
